(0.67%) 5 162.03 points
(0.31%) 38 796 points
(0.72%) 16 273 points
(0.20%) $78.27
(4.30%) $2.23
(0.98%) $2 331.20
(3.49%) $27.62
(0.10%) $966.25
(-0.09%) $0.928
(-0.45%) $10.82
(-0.17%) $0.796
(-0.12%) $91.34
2 days till quarter result
(amc 2024-05-08)
Expected move: +/- 7.20%
0.48% $ 16.91
@ $16.78
Emitido: 14 feb 2024 @ 11:57
Retorno: 0.77%
Señal anterior: feb 13 - 15:50
Señal anterior:
Retorno: 3.13 %
Live Chart Being Loaded With Signals
REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease...
Stats | |
---|---|
Volumen de hoy | 69 428.00 |
Volumen promedio | 742 880 |
Capitalización de mercado | 828.47M |
EPS | $0 ( 2024-05-01 ) |
Próxima fecha de ganancias | ( $-1.280 ) 2024-05-08 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -2.81 |
ATR14 | $0.0280 (0.17%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-04-15 | Mills Kenneth T. | Buy | 15 000 | Common Stock |
2024-04-15 | Mills Kenneth T. | Sell | 15 000 | Common Stock |
2024-04-15 | Mills Kenneth T. | Sell | 15 000 | Stock Options (Right to Buy) |
2024-03-19 | Vasista Vittal | Buy | 20 041 | Common Stock |
2024-03-19 | Vasista Vittal | Sell | 20 041 | Employee Stock Option (Right to Buy) |
INSIDER POWER |
---|
56.05 |
Last 99 transactions |
Buy: 2 306 609 | Sell: 467 606 |
Volumen Correlación
Regenxbio Inc Correlación
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Regenxbio Inc Correlación - Moneda/Commodity
Regenxbio Inc Finanzas
Annual | 2023 |
Ingresos: | $90.24M |
Beneficio Bruto: | $35.71M (39.57 %) |
EPS: | $-6.02 |
FY | 2023 |
Ingresos: | $90.24M |
Beneficio Bruto: | $35.71M (39.57 %) |
EPS: | $-6.02 |
FY | 2022 |
Ingresos: | $112.72M |
Beneficio Bruto: | $58.18M (51.61 %) |
EPS: | $-6.50 |
FY | 2021 |
Ingresos: | $0.00 |
Beneficio Bruto: | $0.00 (0.00 %) |
EPS: | $3.01 |
Financial Reports:
No articles found.
Regenxbio Inc
REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's lead product candidate is RGX-314, which is in Phase III clinical trial for the treatment of wet age-related macular degeneration. It is also developing RGX-121 that is in Phase I/II clinical trial to treat mucopolysaccharidosis type II;RGX-111, which is in Phase I/II clinical trial for treating mucopolysaccharidosis type I;RGX-181 which is in pre clinic stage for the treatment of late-infantile neuronal ceroid lipofuscinosis type II disease;RGX-202, to treat Duchenne muscular dystrophy which is in phase I/II clinical trial; and RGX-381, to treat the ocular manifestations of CLN2 disease which is in preclinical stage. REGENXBIO Inc. also licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies; and has a collaboration and license agreement with Neurimmune AG to develop novel gene therapies. REGENXBIO Inc. was founded in 2008 and is headquartered in Rockville, Maryland.
Acerca de Señales en Vivo
Las señales en vivo presentadas en esta página ayudan a determinar cuándo COMPRAR o VENDER NA. Las señales tienen un retraso de más de 1 minuto; como todas las señales del mercado, existe la posibilidad de error o errores.
Las señales de trading en vivo no son definitivas y getagraph.com no asume ninguna responsabilidad por cualquier acción tomada sobre estas señales, como se describe en los Términos de Uso. Las señales se basan en una amplia gama de indicadores de análisis técnico